Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides

Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides

Cancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy...

Full description

Saved in:

Bibliographic Details
Main Authors:	Quanlan Fu, Yuandong Luo, Junjie Li, Pingping Zhang, Shuxian Tang, Xinyi Song, Jiawei Fu, Mengqi Liu, Rongmi Mo, Ming Wei, Hejie Li, Xiaosong Liu, Tianfang Wang, Guoying Ni
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	Caerin 1 peptide immune checkpoint blockade therapeutic vaccine tumor microenvironment macrophage
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2385654
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Caerin 1.1 and 1.9 peptides induce acute caspase 3/GSDME-mediated pyroptosis in epithelial cancer cells
by: Yuandong Luo, et al.
Published: (2025-04-01)

Caerin 1.1/1.9 interfere KHDRBS1-DDX5 regulatory axis to induce IL-18 mediated pyroptosis in a HeLa cell tumour model
by: Mengqi Liu, et al.
Published: (2025-07-01)

Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model
by: Rongmi Mo, et al.
Published: (2025-05-01)

A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
by: Ginette S. Santiago-Sánchez, et al.
Published: (2024-12-01)

An immune activator encapsulating PD-L1 siRNA for augmented immune checkpoint blockade immunotherapy through Zn2+ overload triggered pyroptosis
by: Liming Gong, et al.
Published: (2025-06-01)

Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression
by: Paul G. Pavicic, et al.
Published: (2023-12-01)

Cytoplasmic HMGB2 orchestrates CALR translocation in the course of immunogenic cell death
by: Peng Liu, et al.
Published: (2024-12-01)

Dendritic cell effector mechanisms and tumor immune microenvironment infiltration define TLR8 modulation and PD-1 blockade
by: Daniel A. Ruiz-Torres, et al.
Published: (2024-12-01)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
by: Niklas Klümper, et al.
Published: (2023-12-01)

PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1
by: Lvyun Zhu, et al.
Published: (2024-12-01)

The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade
by: Yuchen Zhang, et al.
Published: (2024-11-01)

A novel nanomedicine integrating ferroptosis and photothermal therapy, well-suitable for PD-L1-mediated immune checkpoint blockade
by: Yujun Bao, et al.
Published: (2024-12-01)

Injectable celastrol-loading emulsion hydrogel for immunotherapy of low-immunogenic cancer
by: Yu Liu, et al.
Published: (2025-03-01)

Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma
by: Sophie Rovers, et al.
Published: (2025-12-01)

Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model
by: Muhammad Zaeem Noman, et al.
Published: (2025-12-01)

Thioredoxin: a key factor in cold tumor formation and a promising biomarker for immunotherapy resistance in NSCLC
by: Jiayi Hu, et al.
Published: (2025-05-01)

M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance
by: Naisheng Zheng, et al.
Published: (2023-12-01)

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models
by: Brajesh P. Kaistha, et al.
Published: (2024-12-01)

Mutation of isocitrate dehydrogenase indicates favorable outcomes in pan-cancer immune checkpoint blockade
by: Zhiyang Huang, et al.
Published: (2025-02-01)

Decitabine co-operates with the IL-33/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma
by: Francesco Noto, et al.
Published: (2025-05-01)

PD-L1 as a Potential Target in Cancer Therapy (Review)
by: N. N. Andrusova, et al.
Published: (2021-02-01)

Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy
by: Tetsuichi Kansha, et al.
Published: (2025-07-01)

Galectin-9 and Tim-3 in gastric cancer: a checkpoint axis driving T cell exhaustion and Treg-mediated immunosuppression independently of anti-PD-1 blockade
by: Charlotte N. Hill, et al.
Published: (2025-07-01)

Reprogramming tumor-associated macrophages and blocking PD-L1 via engineered outer membrane vesicles to enhance T cell infiltration and cytotoxic functions
by: Zhiqiang Chen, et al.
Published: (2025-07-01)

Lactylation‐Driven NUPR1 Promotes Immunosuppression of Tumor‐Infiltrating Macrophages in Hepatocellular Carcinoma
by: Jialiang Cai, et al.
Published: (2025-05-01)

Editorial: Tumor-associated tertiary lymphoid structures response during immunotherapy
by: Ileana Soto Mauldin, et al.
Published: (2025-04-01)

Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy
by: Qiongjie Hu, et al.
Published: (2025-03-01)

Mitochondria-targeted photothermal-chemodynamic therapy enhances checkpoint blockade immunotherapy on colon cancer
by: Benchao Zheng, et al.
Published: (2025-04-01)

Potentiation of immune checkpoint blockade with an ITPP radiosensitizer studied with oxygen saturation measurements from photoacoustic imaging
by: Renee L. Tran, et al.
Published: (2025-07-01)

Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
by: Saima Jamil Farooqi, et al.
Published: (2024-12-01)

Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1β‐centered loop to attenuate immune checkpoint blockade
by: Cheng Xu, et al.
Published: (2023-04-01)

iMLGAM: Integrated Machine Learning and Genetic Algorithm‐driven Multiomics analysis for pan‐cancer immunotherapy response prediction
by: Bicheng Ye, et al.
Published: (2025-04-01)

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
by: Laura Rubio-Pérez, et al.
Published: (2023-12-01)

Chaperonin containing TCP1 subunit 5 as a novel pan-cancer prognostic biomarker for tumor stemness and immunotherapy response: insights from multi-omics data, integrated machine learning, and experimental validation
by: Jiajun Li, et al.
Published: (2025-05-01)

ADA/CD26 axis increases intra-tumor PD-1+CD28+CD8+ T-cell fitness and affects NSCLC prognosis and response to ICB
by: Ornella Franzese, et al.
Published: (2024-12-01)

CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects
by: Jia-Wen Wang, et al.
Published: (2025-07-01)

Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles
by: Yuxuan Liu, et al.
Published: (2024-11-01)

Immunohistochemical Profiling of Immune Checkpoints in Chronic Hepatitis B Liver Tissue
by: João Panão-Costa, et al.
Published: (2025-06-01)

Predicting immunotherapy prognosis and targeted therapy sensitivity of colon cancer based on a CAF-related molecular signature
by: Leqian Ying, et al.
Published: (2025-02-01)

Neighboring Effect‐Initiated Supramolecular Nanocomplex with Sequential Infiltration as Irreversible Apoptosis Inducer for Synergetic Chemo‐Immunotherapy
by: Mengjie Ye, et al.
Published: (2024-10-01)